Antifungal efficacy of isavuconazole and liposomal amphotericin B in a rabbit model of *Exserohilum rostratum* meningoencephalitis: A preclinical paradigm for management of CNS phaeohyphomycosis

Vidmantas Petraitis1,∗, Ruta Petraitiene1, Aspasia Katragkou1,2, Bo Bo Win Maung1, Patriss W. Moradi1, Gittel E. Sussman-Straus1, Ethan Naing1, Laura L. Kovanda3, Malcolm A. Finkelman4 and Thomas J. Walsh1,5,6

1Transplantation-Oncology Infectious Diseases Program, Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine of Cornell University, New York, New York, USA, 2New York Presbyterian Brooklyn Methodist Hospital, Brooklyn, New York, USA, 3Astellas Pharma Global Development, Inc., Northbrook, Illinois, USA, 4Associates of Cape Cod, Inc., East Falmouth, Massachusetts, USA, 5Department of Microbiology & Immunology, Weill Cornell Medicine of Cornell University, New York, New York, USA and 6Department of Pediatrics, Weill Cornell Medicine of Cornell University, New York, New York, USA

∗To whom correspondence should be addressed. Vidmantas Petraitis, MD, Weill Cornell Medicine, 1300 York Ave., Room A-421, New York, NY 10065, USA. Tel: 1-212-746-7806; Fax: 1-212-746-8675; E-mail: vip2007@med.cornell.edu

Received 1 June 2020; Revised 22 October 2020; Accepted 7 December 2020; Editorial Decision 20 November 2020

Abstract

Treatment options for *Exserohilum rostratum* meningoencephalitis and other causes of phaeohyphomycosis of the central nervous system (CNS) are limited, while mortality and morbidity remain high. We therefore evaluated isavuconazole, a new antifungal triazole in comparison to liposomal amphotericin B (LAMB), in vitro and in the rabbit model of *Exserohilum rostratum* meningoencephalitis. We hypothesized that isavuconazole alone or in combination with LAMB or micafungin may be alternative options for treatment of CNS phaeohyphomycosis. We therefore investigated the in vitro antifungal activity of isavuconazole alone or in combination with amphotericin B deoxycholate (DAMB) or micafungin and efficacy of treatment with isavuconazole and LAMB in a rabbit model of experimental *E. rostratum* meningoencephalitis. Combination checkerboard plates were used to determine the minimum inhibitory concentrations, minimal lethal concentrations, fractional inhibitory concentration indices, and Bliss surface analysis of isavuconazole and amphotericin B deoxycholate (DAMB), either alone or in combination. As there were no in vitro synergistic or antagonistic interactions for either combination of antifungal agents against the *E. rostratum* isolates, in vivo studies were conducted with isavuconazole and LAMB as monotherapies. Rabbits were divided in following groups: treated with isavuconazole at 60 mg/kg/d (ISAV60), LAMB at 5.0 (LAMB5), 7.5 (LAMB7.5), and 10 mg/kg/d (LAMB10), and untreated controls (UC). In ISAV60-, LAMB5-, LAMB7.5-, and LAMB10-treated rabbits, significant reductions of fungal burden of *E. rostratum* in cerebral, cerebellar, and spinal cord tissues (P < 0.01) were demonstrated in comparison to those of UC. These antifungal effects correlated with significant reduction of CSF (1→3)-β-D-glucan levels vs UC (P < 0.05). These data establish new translational insights into treatment of CNS phaeohyphomycosis.

Key words: experimental CNS phaeohyphomycosis, isavuconazole, liposomal amphotericin B, rabbits.
Introduction

Mould infections of the central nervous system (MICNS) are life-threatening diseases with high mortality and morbidity rates. Among the therapeutic options available for treatment of MICNS, those for management of CNS aspergillosis have been well described, however, considerably less is known about the therapeutic options for CNS phaeohyphomycosis. Although voriconazole or liposomal amphotericin B have been recognized as standards of care in treatment of CNS phaeohyphomycosis, both agents have efficacy, safety, and tolerability limitations.

Revankar et al reported that among 26 patients with disseminated phaeohyphomycosis, including 12 with CNS infection, 16 received two or more antifungal agents. Despite the frequent use of combination antifungal therapy, patients with disseminated phaeohyphomycosis had a clinical response of 31% and mortality of 69%. An earlier study of CNS phaeohyphomycosis by Revankar and colleagues also found that overall mortality in this infection was 74%.

Isavuconazole is a recently introduced antifungal triazole with proven clinical efficacy in the treatment of invasive infections caused by Aspergillus and Mucorales. Given the broad spectrum of antifungal activity against pathogenic moulds, we hypothesized that isavuconazole may be a viable alternative for treatment of CNS phaeohyphomycosis. Moreover, we considered that the combination of isavuconazole plus micafungin or the combination of isavuconazole plus liposomal amphotericin B (LAMB) might be synergistic for treatment of CNS phaeohyphomycosis.

Exserohilum rostratum was the etiological agent of the multi-state outbreak in the USA of CNS phaeohyphomycosis caused by the administration of a contaminated methylprednisolone injection preparation. As more than 600 cases of Exserohilum rostratum CNS infection were identified, this infection constitutes the most widely treated form of CNS phaeohyphomycosis documented thus far.

We therefore studied the antifungal activity of isavuconazole alone and in combination with micafungin or amphotericin B deoxycholate (DAMB) against of E. rostratum in vitro and, based upon these findings, proceeded to investigate the efficacy of isavuconazole alone and LAMB alone for the treatment of CNS phaeohyphomycosis in an immunocompromised rabbit model of E. rostratum meningoencephalitis.

Methods

Organisms and in vitro studies

Five isolates of E. rostratum (12-2725, 12-2786, 12-2809, 12-2838, and 12-2840), obtained from patients suffering from E. rostratum meningoencephalitis, as the result of the corticosteroid injection related outbreak, were used in the in vitro experiments.

The CLSI M38-A3 methodology was applied for inoculum preparation of each E. rostratum isolate. Mould isolates were subcultured onto a potato dextrose agar slant (PDA) and incubated at 37°C for 24 h, and then stored for additional 5-7 days at ambient temperature. The conidial suspensions of 0.4-5 × 10^4 CFU/mL were prepared using a 0.025% Tween 20 solution in 0.9% normal saline. The conidial suspensions were measured with a spectrophotometer at 530-nm wavelength and brought to 80-82% transmittance (%T) readings.

We further studied the in vitro antifungal activity of isavuconazole in combination with micafungin or amphotericin B against of E. rostratum based on their activity when administered alone and from previously published data on combination efficacy against Aspergillus fumigatus.

The combination checkerboard plates were prepared according to the CLSI recommendations. An aliquot of 100 μL of the vortexed suspension was inoculated into each well of a 96-well flat-bottom microplate containing 100 μL of single drugs and two-drug combinations of isavuconazole (ISAV; Astellas Pharma Global Development, Inc., Northbrook, IL) plus micafungin (MFG), or ISAV plus deoxycholate amphotericin B (DAMB) (X-GEN Pharmaceuticals, Big Flats, NY). The tested concentrations in checkerboard dilutions ranged from 0.0625 to 32 μg/mL for ISAV, from 0.5 to 32 μg/mL for MFG, and from 0.125 to 8 μg/mL for DAMB. After 48-h incubation at 37°C, optical density (OD) measurements were recorded at 530-nm wavelength. Bliss surface interaction and fractional inhibitory concentration indifference (FICI) indices were then calculated. The minimal inhibitory concentrations (MICs) and minimal lethal concentrations (MLCs) of antifungal drugs were determined, and fractional inhibitory concentration (FIC) indices were calculated.

The MICs were determined as optically clear wells. The MLCs were determined as wells that produced no fungal growth once plated on PDA plates. Additional analysis was performed using Bliss surface interaction analysis, as previously described.

Inoculum preparation and inoculation procedures for in vivo studies

The previously studied E. rostratum isolates 12–2725 and 12–2809 were used in all in vivo experiments. In order to detect differences in the in vivo response, we selected two isolates based on our preliminary in vitro data: one isolate with lower MIC to isavuconazole and the other with higher MIC. Although the MICs were different for two isolates, we did not observe significant differences in the in vivo response to treatment. Therefore, the data were pooled, presented, and analyzed in aggregate.

Inoculum preparation and inoculation were performed as previously described. In brief, E. rostratum isolates were subcultured onto PDA plates, incubated at 37°C for 24 h, and maintained inverted for 1-2 weeks. Then multiple plates were filled with 10 mL of 0.025% Tween-20 saline solution and gently
scraped with a 10-mL pipette. The resulting suspensions of *E. rostratum* were combined into 50-mL conical tubes. After tubes were centrifuged, the supernatant and floating fungal elements were removed leaving 5 mL in the tubes, combined, and conidia were resuspended in 0.025% Tween-20 saline solution into a final volume, based upon the number of *E. rostratum* conidia counted with a hemacytometer. Following vigorous vortexing, aggregation of the conidia was negligible but when present, was considered as a single infecting unit. The final concentration of *E. rostratum* was 1.0 × 10⁶ CFU of conidia. 500 μL of inoculum was administered to anesthetized rabbits, as previously described,⁰⁻²⁰ intracisternally in the amount of 500 μL for each rabbit, after equal amount of CSF (500 μL) was withdrawn from the cisterna magna before inoculation. The inoculum concentrations were verified by serial dilutions on Sabouraud glucose agar plates.

**Animals**

Female New Zealand White rabbits (Envigo RMS, Inc. Denver, PA) were used for all studies. At the time of intracisternal inoculation, rabbits weighted 2.6-3.6 kg. All groups were included in the same experiment, which was conducted in replicate. All rabbits were monitored under humane care and use standards in facilities, accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International, according to the guidelines of the National Research Council for the care and use of laboratory animals.²¹ The experiments were approved by the Animal Care and Use committee of the Weill Cornell Medicine, New York, NY. Rabbits had an indwelling Silastic central venous catheter, placed under general anesthesia, for the atraumatic collection of diagnostic samples and the parenteral administration of investigational agents, as well as compounds required to induce and support neutropenia.

**Immunosuppression and maintenance of neutropenia**

Induction of profound persistent neutropenia and immunosuppression was initiated 6 days before intracisternal inoculation and maintained using cytarabine (Ara-C) (Cytarabine injection; Hospira, Inc., Lake Forest, IL) at a dosage of 440 mg/m² for 5 consecutive days (days 1-5) with subsequent administration on days 8-9 and 13-14, as previously described.²⁰ Methylprednisolone (Solu-Medrol®, Pfizer Inc., NY, NY) was administered intravenously beginning on day 4 of the study to prevent bacterial infections. Vancomycin (50 mg/L) was added to the drinking water to prevent antibiotic-associated diarrhea due to *Clostridium spiroforme* from the beginning of induction of neutropenia.

**Inoculum-response studies**

In order to define the optimal *E. rostratum* inoculum, initial studies were conducted in three inoculum groups of four rabbits each to investigate the fungal burden in cerebral, cerebellar, and spinal cord tissues after intracisternal inoculation of defined suspensions of 1.0 × 10³, 1.0 × 10⁴, and 1.0 × 10⁶ conidia. A total of four animals were used in each of the three inoculum groups. Following euthanasia at the end of the study or because of humane end points, cerebral, cerebellar, and spinal cord tissue samples were harvested and quantitative fungal cultures were performed.

**Antifungal agents and experimental groups**

Isavuconazole was administered as an oral formulation of isavuconazonium sulfate. Prodrug isavuconazonium sulfate powder was dissolved in sterile water and mixed with the same amount of 5% dextrose injection solution (DSW; Baxter Healthcare Corp., Deerfield, IL) for oral administration. The oral dosage of 60 mg/kg/d was based upon the active moiety isavuconazole. LAMB (AmBisome, Astellas Pharma Global Development, Inc., Northbrook, IL) was administered intravenously in dosages of 5, 7.5, and 10 mg/kg/d.

Antifungal therapy was initiated on day 7 (1 day after inoculation) and continued throughout the experiment for 13 days in surviving rabbits. Study groups consisted of isavuconazole at 60 mg/kg/d (ISA60, n = 8), LAMB at 5.0 (LAMB5, n = 8), 7.5 (LAMB7.5, n = 8), and 10 mg/kg/d (LAMB10, n = 8), and untreated controls (UC, n = 14).

**Outcome variables**

Quantitative clearance of *E. rostratum* from CNS tissues and declines of CSF (1→3)-β-D-glucan levels were used to assess in vivo antifungal activity.

**Quantitative cultures.** The representative sections of CNS tissues were obtained and processed, as previously described.²⁰ Briefly, resected tissue sections were weighed, and homogenized with 2 or 5 mL of sterile 0.9% normal saline for 30 s.²² The aliquots (100 μL) of tissue homogenates and dilutions (10⁻¹ and 10⁻²) were plated onto Sabouraud glucose agar plates and incubated at 37°C for 24 h. After 48 h, residual fungal colonies were counted and data were plotted as the mean log CFU/g ± standard error of the mean (SEM).

(1→3)-β-D-glucan assay. To determine CSF (1→3)-β-D-glucan levels, a sample from each rabbit was collected on the last day of experiment just after euthanasia. Levels of (1→3)-β-D-glucan were determined by assay according to the manufacturer’s instructions (Fungitell®; Associates of Cape Cod,
Inc., Falmouth, MA) as previously described. Briefly, a 96-well microtiter plate was filled with aliquots of 5 μL of CSF and pre-treated for 10 min at 37°C with an alkaline reagent (20 μL; 0.125 M KOH/0.6 M KCl). An aliquot of 25 μL of the standards was then added to wells designated for the standard curve. An aliquot of 100 μL of mixture of Fungitell® reagent (reconstituted with 2.8 mM glucan-free reagent-grade water plus 2.8 mL Pyrosol reconstitution buffer) was added to each sample. The plate was monitored at 405 nm minus 490 nm for 40 min at 37°C by using a Bio-Tek ELx808 automated microplate reader (Bio-Tek Instruments, Inc., Winooski, VT). The mean rate of optical density change was determined for each well, and the glucan concentration was determined by comparison to the standard curve. When absorbance was outside the range of the standard curve, the CSF samples were serially diluted in reagent-grade water and tested again. Values were plotted as mean (1→3)-β-d-glucan concentrations in picograms per milliliter in CSF for each study group.

### Statistical analysis

In vitro interaction for combinations was assessed by Bliss surface interaction analysis, as previously described. Comparisons between groups in vivo were performed by using the nonparametric analysis of Mann-Whitney U-test. A two-tailed P value of ≤0.05 was considered to be statistically significant. Since, there were no significant differences in outcome variables between *E. rostratum* isolates 12–2725 and 12–2809 used in in vivo experiments, data were pooled together. Values are expressed as means and standard error of the means (SEMs).

### Results

#### In vitro combination studies

There was no synergistic or antagonistic interaction for combinations of isavuconazole plus micafungin and of isavuconazole plus DAMB against clinical isolates of *E. rostratum* as measured by MIC and FICI indices (Table 1). Similar data demonstrating no synergistic or antagonistic interaction was observed when measured by Bliss surface interaction analysis. Subsequent studies of antifungal efficacy in vivo of *E. rostratum* meningoencephalitis experimental rabbit model were thus conducted with single agent monotherapy of isavuconazole or LAMB.

### Inoculum–response studies

There was a direct inoculum-response relationship. A threshold intracisternal inoculum of ≥10^4 conidia was required to establish experimental *E. rostratum* meningoencephalitis. A higher inoculum was associated with a significantly greater level of residual fungal burden in cerebral, cerebellar, and spinal cord tissues. Based on these results, an inoculum of 1.0 × 10^6 conidia was selected for the efficacy studies in rabbits (Figure 1).

#### In vivo efficacy studies

Rabbits treated with isavuconazole at 60 mg/kg/d, LAMB at 5 mg/kg/d, 7.5 mg/kg/d, and 10 mg/kg/d demonstrated a significant decrease of fungal burden in cerebral, cerebellar, and spinal cord tissues (P<0.05), when compared to UC (Figure 2). The efficacy of isavuconazole at 60 mg/kg/d was comparable in efficacy to that of LAMB at 5, 7.5, and 10 mg/kg/d. Although two isolates were selected with low and high MICs for in vivo studies, there was no significant difference in therapeutic response between the isolates. There were significant reductions in CSF (1→3)-β-d-glucan levels in rabbits treated with isavuconazole at 60 mg/kg/d, when compared to UC (P<0.05). There also was a trend toward decreased levels of CSF (1→3)-β-d-glucan in rabbits treated with LAMB at 5, 7.5, and 10 mg/kg/d; however, these values did not reach statistical significance (Figure 3).

### Discussion

This study demonstrated that monotherapy with isavuconazole or LAMB significantly reduced residual fungal burden in cerebral, cerebellar, and spinal cord tissues in parallel with decreased CSF (1→3)-β-d-glucan levels in experimental *E. rostratum* CNS phaeohyphomycosis. Both isavuconazole and LAMB were comparable in efficacy in reduction of residual tissue burden.

| *E. rostratum* isolate | (MIC; MLC) (μg/mL) | Combination (I-Independent) |
|------------------------|---------------------|----------------------------|
| ISAV                   | MFG                 | ISAV + MFG Bliss; FICI     |
| ISAV + DAMB Bliss; FICI|
| 12-2725               | (0.5; >4.0)         | (I; 0.49)                  |
|                       | (0.25; >8.0)        | (I; N/A)                   |
| 12-2786               | (4.0; 4.0)          | (I; 1.0)                   |
|                       | (0.25; >8.0)        | (I; 1.06)                  |
| 12-2838               | (1.0-2.0; >4.0)     | (I; 0.88)                  |
|                       | (2.0-4.0; >8.0)     | (I; N/A)                   |
| 12-2809               | (4.0; >4.0)         | (I; N/A)                   |
|                       | (>8.0; >8.0)        | (I; N/A)                   |
| 12-2840               | (2.0; >4.0)         | (I; N/A)                   |
|                       | (0.06; >8.0)        | (I; N/A)                   |
in treatment of *E. rostratum* meningoencephalitis-related CNS phaeohyphomycosis. In vitro microdilution checkerboard studies demonstrated that the combination of isavuconazole plus micafungin or isavuconazole plus DAMB showed no synergistic or antagonistic interaction, thus warranting study of in vivo monotherapy. Results from this study provide a translational rationale for further study of isavuconazole or LAMB as monotherapy for treatment of CNS phaeohyphomycosis.

Isavuconazole possesses considerable advantage over voriconazole for the potential of long-term usage in treatment of CNS phaeohyphomycosis. A randomized trial of isavuconazole versus voriconazole demonstrated significantly fewer adverse events related to clinical toxicity, including hepatic injury, photopsia, visual hallucinations, and cutaneous hypersensitivity. Moreover, in most patients, isavuconazole has a predictable pharmacokinetic profile that minimizes the need for serial therapeutic drug monitoring. Finally, isavuconazole, which is metabolized primarily through CYP3A4, has fewer drug–drug interactions compared to that of voriconazole, which is metabolized through CYP3A4, CYP2C9, and CYP2C19.

LAMB also was effective as monotherapy at dosages ranging from 5 to 10 mg/kg/d. Responses were similar across the dosage range of 5 to 10 mg/kg/d. As the plasma exposures of LAMB achieved in the rabbit model are similar to those in humans, a dosage of 5 mg/kg/d can be considered in treatment of human CNS infection, thus avoiding higher dosages, which show dose-dependent-nephrotoxicity. Other studies against invasive aspergillosis have found that dosages > 5 mg/kg/d may not be more effective but may be more nephrotoxic. Moreover, isavuconazole would have an overall clinical advantage with minimal nephrotoxicity, as it demonstrated in the study herein that is comparable therapeutically to LAMB.

All isolates of *E. rostratum* that were investigated in this study were recovered from patients infected by contaminated corticosteroid injections related to the outbreak. A full background of each patient’s clinical history for each respective isolate was not known. Among possible explanations of the inter-isolate variability of MICs for selected compounds are antifungal exposures before recovery of the organism, micro-evolution in the inanimate environment of the solution, or extant heteroresistance among the isolates.

The potential for combination therapy of isavuconazole plus micafungin was investigated predicated on the observations for the combination of micafungin plus isavuconazole against *A. fumigatus* in vitro and invasive pulmonary aspergillosis in vivo. The synergistic interaction between mould-active triazoles and

---

**Figure 1.** Scattergrams of inoculum–response, as measured by CFU/g in CNS tissues, including cerebrum, cerebellum, and spinal cord, versus CFU/inoculum of *Exserohilum rostratum* in immunocompromised rabbit model of meningoencephalitis. A bar through the column of each group represents the median log₁₀ CFU/g for that group. There were four rabbits in each of three inoculum groups. Data were pooled from *E. rostratum* 12–2725 and *E. rostratum* 12–2809 results.
Figure 2. Scattergrams of response to antifungal therapy in persistently neutropenic rabbit model of Exserohilum rostratum meningoencephalitis. Antifungal efficacy was measured by mean tissue residual fungal burden (log CFU/g) in CNS tissues, including cerebrum, cerebellum, and spinal cord. Significant decrease in residual fungal burden in rabbits treated with isavuconazole at 60 mg/kg/d, liposomal amphotericin B at 5, 7.5, and 10 mg/kg/d were observed when compared to untreated controls (UC). There were eight rabbits (four rabbits per each isolate) in each of treatment groups, and 14 untreated controls. Data were pooled from E. rostratum 12–2725 and E. rostratum 12–2809 results. A bar through the column of each group represents the median log10 CFU/g for that group.*

Figure 3. Scattergrams of detected CSF (1→3)-β-d-glucan levels in persistently neutropenic rabbit model of Exserohilum rostratum meningoencephalitis in untreated controls (UC, n = 5), and rabbits treated orally with isavuconazole at 60 mg/kg/d, and intravenously (n = 4) with LAMB at 5 mg/kg/d (n = 3), 7.5 mg/kg/d (n = 3), and 10 mg/kg/d (n = 3). Values are given as (1→3)-β-d-glucan concentrations picograms per milliliter. * P < 0.05: significant decrease of CSF (1→3)-β-d-glucan levels in rabbits treated with isavuconazole at 60 mg/kg/d in comparison to that of UC. Data were pooled from results of E. rostratum isolates 12–2725 and 12–2809. A bar through the column of each group represents the median (1→3)-β-d-glucan level (pg/mL) for that group.

Expression of (1→3)-β-d-glucan level in CSF

Echinocandins against A. fumigatus has been well documented in repeated studies in vitro and in vivo, particularly in the persistently neutropenic rabbit invasive pulmonary aspergillosis.17,27,28 These in vitro and in vivo findings were predictive of the outcome of the randomized controlled clinical trial of voriconazole plus anidulafungin versus voriconazole alone. This study demonstrated a trend toward improved fungal free survival in the primary endpoint, and in the post hoc test analysis showed significant improvement of survival in patients with probable invasive pulmonary aspergillosis with galactomannan-positive infection.29

The paucity of a synergistic interaction between isavuconazole and micafungin against E. rostratum underscores the importance for investigation of potential synergistic combinations against different non-Aspergillus moulds. While the synergistic combination of mould-active triazole and echinocandin are well documented for Aspergillus fumigatus and invasive pulmonary aspergillosis, differences in antifungal efficacy in phaeohyphomycetes may be related to the presence of melanin in cell walls, which may prevent a synergistic effect.

A direct inoculum response relationship was observed from $1.0 \times 10^2$ to $1.0 \times 10^6$ CFU in the model of E. rostratum.
mengoencephalitis with a threshold for infection at $\geq 1.0 \times 10^4$ CFU. This observation may have important implications for understanding the infection dynamics of the multi-state outbreak of *E. rostratum* meningoencephalitis that infected more than 500 patients.32 During the outbreak, direct inoculation of contaminated solutions of methylprednisolone to approximately 14 000 patients occurred, yet most did not develop a clinically overt infection. Among the potential explanations for this observation may have been variable contamination of the vials with quantitatively higher levels of contamination accounting for those patients who developed clinical evidence of infection, where a threshold for infection was achieved. Other factors that would also have contributed may have been injected volume, the number of repeated injections, and host factors that may have increased the risk of disease.

Some patients with *E. rostratum* meningoencephalitis were reported to have paravertebral muscle infection. We therefore conducted a pilot investigation of paravertebral muscle infection within this study. These experiments demonstrated paravertebral muscle tissue infection in the model, further reflecting the similarity of this model to that of human infection.

Phaeohyphomycosis of the CNS is caused by a wide range of dematiaceous moulds. With more than 600 patients with infection of the brain and/or spinal cord caused by *E. rostratum*,4,30 this pathogen has caused the most recorded cases of CNS phaeohyphomycosis of all dematiaceous moulds. We therefore replicated the pattern of CNS infection caused by *E. rostratum* and investigated it for treatment of CNS phaeohyphomycosis. Other brown/black pigmented moulds may also be modeled; however, some pathogens would require a different route of inoculation; for example, *Cladophialophora bantiana*, which was the most common cause of CNS phaeohyphomycosis in the prospective series by Revankar et al,4 presents typically as solitary or multiple brain abscesses with minimal meningeal involvement.31-33 Thus, *Cladophialophora bantiana* CNS phaeohyphomycosis would likely be modeled as a pulmonary or intravenous portal of entry with hematogenous dissemination.34,35

In summary, isavuconazole at 60 mg/kg/d, LAMB at 5.0 mg/kg/d, LAMB 7.5 mg/kg/d, and LAMB 10 mg/kg/d as monotherapies were found to significantly decrease the residual fungal burden of *E. rostratum* by as much as 100-fold in cerebral, cerebellar, and spinal cord tissues. We conclude that isavuconazole is a promising agent with in vivo activity comparable to that of LAMB in treatment of *E. rostratum* meningoencephalitis and may be effective in other forms of CNS phaeohyphomycosis.

Acknowledgments

This study was supported in part by a collaborative research grant from Astellas Pharma Global Development. Liposomal amphotericin B and isavuconazole were provided by Astellas Pharma, which also markets these antifungal agents in the United States. The authors thank Davise Larone, Andrew Garcia, and Povilas Kavaliauskas for their contributions to this study.

Declaration of Interest

Dr. Walsh has received grants for experimental and clinical antimicrobial pharmacology and therapeutics to his institution from AllerGAN, Amplyx Pharmaceuticals, Astellas Pharma, Leadiant Biosciences, Medicines Company, Merck, Syneix, and Tetraphase Pharmaceuticals and has served as consultant to Amplyx Pharmaceuticals, Astellas Pharma, AllerGAN, ContraFect, Gilead Sciences, Leadiant Biosciences, Medicines Company, Merck, Methylgene, Pfizer, and Syneix. Dr. Kovanda is employee at Astellas Pharma Global Development, Inc., Northbrook, Illinois, USA. Dr. Finkelman is an employee of Associates of Cape Cod, Inc., Falmouth, Massachusetts, USA. The other authors have no other declarations of interest.

References

1. McCarthy M, Rosengart A, Schuetz AN, Kontoyiannis DP, Walsh TJ. Mould infections of the central nervous system. *N Engl J Med*. 2014; 371: 150–160.
2. Patterson TF, Thompson GR 3rd, Denning DW et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. *Clin Infect Dis*. 2016; 63: e1–e60.
3. Warris A, Lehnbecher T, Roilides E et al. ESCMID-ECCM guideline: diagnosis and management of invasive aspergillosis in neonates and children. *Clin Microbiol Infect*. 2019; 25: 1096–1113.
4. Revankar SG, Sutton DA, Rinaldi MG. Primary central nervous system phaeohyphomycosis: a review of 101 cases. *Clin Infect Dis*. 2004; 38: 206–216.
5. Velasco J, Revankar S. CNS infections caused by brown-black fungi. *J Fungi*. 2019; 5: 60.
6. Maertens JA, Raad II, Marr KA et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by *Aspergillus* and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. *Lancet*. 2016; 387: 760–769.
7. Marty FM, Ostrosky-Zeichner L, Cornely OA et al. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. *Lancet Infect Dis*. 2016; 16: 828–837.
8. Chowdhary A, Hagen F, Curfs-Breuker I et al. In vitro activities of eight antifungal drugs against a global collection of genotyped *Exserohilum* isolates. *Antimicrob Agents Chemother*. 2015; 59: 6642–6645.
9. Zheng H, He Y, Kan S et al. In vitro susceptibility of dematiaceous fungi to nine antifungal agents determined by two different methods. *Mycooses*. 2019; 62: 384–390.
10. Abbas KM, Dorratoltaj N, O’Dell ML et al. Clinical response, outbreak investigation, and epidemiology of the fungal meningitis epidemic in the United States: systematic review. *Disaster Med Public Health Prep.* 2016; 10: 145–151.
11. Chiller TM, Roy M, Nguyen D et al. Clinical findings for fungal infections caused by methylprednisolone injections. *N Engl J Med*. 2013; 369: 1610–1619.
12. Larone DH, Walsh TJ. *Exserohilum rostratum*: anatomy of a national outbreak of fungal meningitis. *Clin Microbiol Newslett.* 2013; 35: 185–193.
13. Pettit AC, Malani AN. Outbreak of fungal infections associated with contaminated methylprednisolone acetate: an update. *Curr Infect Dis Rep* 2015; 17: 441.
14. Renfrow JJ, Frenkel MB, Hsu W. Fungal contamination of methylprednisolone causing recurrent lumbosacral intradural abscess. *Emerg Infect Dis*. 2017; 23: 532–533.
15. Zhao Y, Petraitis R, Walsh TJ, Perlin DS. A real-time PCR assay for rapid detection and quantification of *Exserohilum rostratum*, a causative pathogen of fungal meningitis associated with injection of contaminated methylprednisolone. *J Clin Microbiol*. 2013; 51: 1034–1036.
16. CLSI. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi; Approved Standard - Second Edition. CLSI document M38-A2. Wayne, PA: Clinical and Laboratory Standards Institute 2008.
17. Petraitis V, Petraitiene R, McCarthy MW et al. Combination therapy with isavuconazole and micafungin for treatment of experimental invasive pulmonary aspergillosis. *Antimicrob Agents Chemother.* 2017; 61.

18. Petraitis V, Meletiadis J, Katragkou A et al. *In vitro interaction between isavuconazole and micafungin or amphotericin B against medically important moulds.* 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Denver, Colorado, USA, 2013.

19. Meletiadis J, Stergiopoulou T, O’Shaughnessy EM, Peter J, Walsh TJ. Concentration-dependent synergy and antagonism within a triple antifungal drug combination against *Aspergillus* species: analysis by a new response surface model. *AAC* 2007; 51: 2053–2064.

20. Petraitiene R, Petraitis V, Maung BW et al. Posaconazole alone and in combination with caspofungin for treatment of experimental *Exserohilum rostratum* meningoencephalitis: developing new strategies for treatment of phaeohyphomycosis of the central nervous system. *J Fungi.* 2020; 6: 33.

21. Committee for the Update of the Guide for the Care and Use of Laboratory Animals; National Research Council. *Guide for the Care and Use of Laboratory Animals.* 8th ed. Washington, DC: National Academy Press; 2011.

22. Walsh TJ, McEntee C, Dixon DM. Tissue homogenization with sterile reinforced polyethylene bags for quantitative culture of *Candida albicans.* *J Clin Microbiol.* 1987; 25: 931–932.

23. McCarthy MW, Moriyama B, Petraitis R, Walsh TJ, Petraitis V. Clinical pharmacokinetics and pharmacodynamics of isavuconazole. *Clin Pharmacokinet.* 2018; 57: 1483–1491.

24. Andes D, Kovanda L, Desai A et al. Isavuconazole concentration in real-world practice: consistency with results from clinical trials. *Antimicrob Agents Chemother.* 2018; 62.

25. Cornely OA, Maertens J, Bresnik M et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). *Clin Infect Dis.* 2007; 44: 1289–1297.

26. Walsh TJ, Goodman JL, Pappas P et al. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with *Aspergillus* species and other filamentous fungi: maximum tolerated dose study. *Antimicrob Agents Chemother.* 2001; 45: 3487–3496.

27. Petraitis V, Petraitiene R, Hope WW et al. Combination therapy in treatment of experimental pulmonary aspergillosis: *in vitro* and *in vivo* correlations of the concentration- and dose- dependent interactions between amiodafungin and voriconazole by Bliss independence drug interaction analysis. *AAC.* 2009; 53: 2382–2391.

28. Petraitis V, Petraitiene R, Sarafandi AA et al. Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. *J Infect Dis.* 2003; 187: 1834–1843.

29. Marr KA, Schlamm HT, Herbrecht R et al. Combination antifungal therapy for invasive aspergillosis: a randomized trial. *Ann Intern Med.* 2015; 162: 81–89.

30. Smith RM, Schaefer MK, Kainer MA et al. Fungal infections associated with contaminated methylprednisolone injections. *N Engl J Med.* 2013; 369: 1598–1609.

31. Ahmad M, Jacobs D, Wu HH et al. *Cladophialophora bantiana*: a rare intracerebral fungal abscess-case series and review of literature. *Surg J.* 2017; 3: e62–e68.

32. Chakrabarti A, Kaur H, Rudramurthy SM et al. Brain abscess due to *Cladophialophora bantiana*: a review of 124 cases. *Med Myco.* 2016; 54: 111–119.

33. Dixon DM, Walsh TJ, Merz WG, McGinnis MR. Infections due to *Xylohypha bantiana* (*Cladosporium trichoides*). *Clin Infect Dis.* 1989; 11: 515–525.

34. Al-Abdely HM, Najvar LK, Bocanegra R, Graybill JR. Antifungal therapy of experimental cerebral phaeohyphomycosis due to *Cladophialophora bantiana*. *AAC.* 2005; 49: 1701–1707.

35. Walsh TJ, Dixon DM, Polak A, Salkin IF. Comparative histopathology of *Dactyliaria constricta, Fonsecaea pedrosoi, Wangiella dermatitidis,* and *Xylohypha bantiana* in experimental phaeohyphomycosis of the central nervous system. *Mykosen.* 2009; 30: 215–225.